[Hyposensitization in pollinosis. Results of a 3-year controlled study with 2 depot-allergoid grass pollen extracts: aluminum hydroxide-adsorbed allergoid and tyrosine-adsorbed allergoid].
For controlled hyposensitization treatment over a period of three years 36 patients with confirmed grass pollen sensitization had been selected in 1986 and randomly distributed to receive preseasonal injection therapy: 23 patients were treated with an average of seven AGD (aluminium-adsorbed allergoid) injections, and 13 patients had received six TA (tyrosine-adsorbed allergoid) injections. Evaluation of the trial data collected during three years of preseasonal treatment showed the following results of tolerance and efficacy: Systemic side-reactions registered during therapy were only mild and transient and occurred in the average after 3% of the AGD injections and after 10% of the TA injections. Local reactions over 5 cm diameter were registered after 7% in the AGD group and after 9% in the TA group. Before therapy there was no significant difference (p greater than 0.05) between the groups; after three years of therapy the AGD injections had resulted in a mean net rise of specific IgG of 220% (significant, p = 0.001); during the same time, TA injections had resulted in a final net increase of 10% (not significant, p greater than 0.05). Both treatment forms did not lead to any statistically relevant changes of specific IgE values. After three years of hyposensitization treatment, patients of both groups had improved; but an advantage was documented for patients treated with AGD on the basis of scores for objective assessment as well as for registered symptom and medication scores.
Mühlethaler
K
K
Dermatologische Klinik, Universität Zürich.
Wüthrich
B
B
Peeters
A G
AG
Terki
N
N
Girard
J P
JP
Frank
E
E
D000328:Adult; D000485:Allergens; D000080384:Allergoids; D000536:Aluminum Hydroxide; D002986:Clinical Trials as Topic; D003888:Desensitization, Immunologic / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D010936:Plant Extracts / Q000627:therapeutic use*; D011058:Pollen / Q000276:immunology*; D006255:Rhinitis, Allergic, Seasonal / Q000628:therapy*; D014443:Tyrosine
D000485:Allergens; D000080384:Allergoids; D010936:Plant Extracts; D014443:Tyrosine; D000536:Aluminum Hydroxide
Zur Hyposensibilisierung der Pollinose. Ergebnisse einer kontrollierten Studie über drei Jahre mit zwei Depotallergoid-Graspollenextrakten: Aluminiumhydroxid-adsorbiertes Allergoid (AGD) und Tyrosin-adsorbiertes Allergoid (TA).